Regeneron Pharmaceutical’s fourth-quarter profit was negatively impacted after sales of its COVID antibody cocktail dried up and lackluster sales of its blockbuster eye drug, Eylea, but sales of its eczema drug Dupixent helped recover some losses. The pharmaceutical company’s quarterly report, released on Feb. 3, saw earnings initially fall by 46 percent due to reports of…